Medicines labeled for the same conditions
Alternatives to sacituzumab govitecan
12 other medicines are given the same way (intravenous) and in the same FDA class as sacituzumab govitecan or labeled mainly for the same use (breast cancer); the others include 4 her2/neu receptor antagonists, 3 microtubule inhibitors and 1 nucleoside metabolic inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as sacituzumab govitecan?
Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Sacituzumab govitecan | this medicine | none listed | n/a | Yes | No current entry |
| Docetaxelmicrotubule inhibitor | Breast cancer | 14 labelers | n/a | Yes | A presentation being discontinued |
| Paclitaxelmicrotubule inhibitor | Breast cancer | 20 labelers | n/a | Yes | No current entry |
| Gemcitabinenucleoside metabolic inhibitor | Breast cancer | 10 labelers | n/a | No | No current entry |
| Eribulinmicrotubule inhibitor | Breast cancer | 14 labelers | n/a | No | No current entry |
| Trastuzumabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Margetuximabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Trastuzumab emtansine | Breast cancer | none listed | n/a | Yes | No current entry |
| Trastuzumab-strfher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Fulvestrantestrogen receptor antagonist | Breast cancer | 1 labeler | n/a | No | A presentation being discontinued |
| Ixabepilone | Breast cancer | none listed | n/a | Yes | No current entry |
| Pertuzumabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Trastuzumab deruxtecan | Breast cancer | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Sacituzumab govitecan: the full record
- label, generics, price, shortages, recalls